Log In
BCIQ
Print this Print this
 

CJ-12420, RQ-00000004

  Manage Alerts
Collapse Summary General Information
Company RaQualia Pharma Inc.
DescriptionCompetitive acid pump antagonist that inhibits binding of potassium ion to H+/K ATPase
Molecular Target H+/K ATPase pump
Mechanism of ActionH+/K+ ATPase pump inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationGastroesophageal reflux disease (GERD)
Indication DetailsTreat erosive esophagitis; Treat gastroesophageal reflux disease (GERD)
Regulatory Designation
PartnerCJ Group

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/22/2015

Undisclosed

Undisclosed

Undisclosed

09/06/2010

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today